Baloxavir
- Generic Name
- Baloxavir
- Drug Type
- Small Molecule
- Chemical Formula
- C24H19F2N3O4S
- CAS Number
- 1985605-59-1
- Unique Ingredient Identifier
- 4G86Y4JT3F
- Background
Baloxavir is under investigation in clinical trial NCT04327791 (Combination Therapy With Baloxavir and Oseltamavir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)).
Safety and Efficacy of ADC189 in Children 2-11 Years Old With Influenza
- Conditions
- Influenza Type AInfluenza Type B
- Interventions
- Drug: ADC189 tabletsDrug: Placebo of Baloxavir Marboxil tabletsDrug: Placebo of ADC189 tabletsDrug: Placebo of ADC189 granules
- First Posted Date
- 2024-07-18
- Last Posted Date
- 2024-07-18
- Lead Sponsor
- Jiaxing AnDiCon Biotech Co.,Ltd
- Target Recruit Count
- 165
- Registration Number
- NCT06507813
- Locations
- 🇨🇳
Beijing Children's Hospital,Capital Medical University, Beijing, Beijing, China
A Prospective, Multicenter, Randomized Controlled Clinical Study on the Efficacy and Safety of Xuanfei Baidu Granule in the Treatment of Influenza A
- Conditions
- Influenza A
- Interventions
- First Posted Date
- 2024-01-16
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 584
- Registration Number
- NCT06205641
- Locations
- 🇨🇳
Beijing Chaoyang Hospital, Beijing, China
A Phase 2 Trial Comparing Antiviral Treatments in Early Symptomatic Influenza
- Conditions
- InfluenzaInfluenza, Human
- Interventions
- First Posted Date
- 2022-12-13
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- University of Oxford
- Target Recruit Count
- 3000
- Registration Number
- NCT05648448
- Locations
- 🇧🇷
Universidade Federal de Minas Gerais, Minas Gerais, Brazil
🇱🇦Laos-Oxford-Mahosot Wellcome Trust Research unit, Vientiane, Lao People's Democratic Republic
🇳🇵Sukraraj Tropical & Infectious Disease Hospital, Kathmandu, Nepal
Baloxavir Versus Oseltamivir for Nursing Home Influenza Outbreaks
- Conditions
- Influenza, HumanInfluenzaInfluenza -Like Illness
- Interventions
- First Posted Date
- 2021-08-19
- Last Posted Date
- 2023-03-15
- Lead Sponsor
- Insight Therapeutics, LLC
- Target Recruit Count
- 1000
- Registration Number
- NCT05012189
- Locations
- 🇺🇸
Insight Therapeutics, LLC, Norfolk, Virginia, United States
COmbination Therapy With Baloxavir and Oseltamivir 1 for Hospitalized Patients With Influenza (The COMBO Trial 1)
- First Posted Date
- 2020-03-31
- Last Posted Date
- 2023-10-30
- Lead Sponsor
- Bassett Healthcare
- Target Recruit Count
- 60
- Registration Number
- NCT04327791
- Locations
- 🇺🇸
Bassett Medical Center, Cooperstown, New York, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸Baystate Medical Center, Springfield, Massachusetts, United States
A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2019-05-08
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 1436
- Registration Number
- NCT02954354
Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications
- Conditions
- Influenza
- Interventions
- First Posted Date
- 2016-10-31
- Last Posted Date
- 2019-11-19
- Lead Sponsor
- Shionogi
- Target Recruit Count
- 2184
- Registration Number
- NCT02949011
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.